#route90
March 11, 2026 at 2:30 AM
"Man that construction on Keewatin is bad, I guess we can take Route90. Nope, construction on Route90 as well. Uh, McPhillips? Also constuction. Arlington's bridge is closed... not going all the way to Salter..."
August 29, 2025 at 7:15 PM
Big news from ABK Biomedical🎉 We’ve completed enrollment in ROUTE90, our pivotal FDA study evaluating Eye90 microspheres for primary liver cancer (HCC).

120 patients. International sites. The largest prospective FDA IDE trial ever run for Y90 radioembolization.

#livercancer #HCC #Oncology
ABK Biomedical Completes Enrollment in ROUTE90 Pivotal Study for Primary Liver Cancer
/PRNewswire/ - ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable...
www.prnewswire.com
February 24, 2026 at 2:58 PM
Sharing the observations made by Dr. William Rilling and the Route90 study team at Medical College of Wisconsin. Great Eye90 microspheres insight!

Read more: cancer.mcw.edu/stories/rout...
ROUTE 90 Trial Brings Cutting-Edge Radiation Therapy to Patients with Liver Cancer | Medical College of Wisconsin Cancer Center
A multi-center trial is testing a next-generation therapy that delivers targeted radiation directly to tumors with greater precision and visibility than ever before.
cancer.mcw.edu
December 19, 2025 at 10:44 PM
ABK is proud to share that the first Canadian patient has been successfully treated with Eye90 microspheres® as part of the Route90 clinical trial.

A sincere thank you to Dr. Rajvot Dhatt, his outstanding team at Vancouver General Hospital, and all other contributors supporting this study.
November 21, 2025 at 11:46 PM
Did you know it’s Interventional Oncology (IO) Awareness Week?

ABK Biomedical is proud to support & contribute to the growing field of IO with an innovative approach to radioembolization with Eye90 microspheres® and our Route90 clinical trial.
www.ioawareness.org
#IOAwarenessWeek #Y90 #IKnowIO
October 29, 2025 at 1:40 AM
The latest article on Y-90 in Radiation Oncology highlights the increasing body of evidence supporting its use in treating patients w/liver cancer. ABK’s anticipated Route90 study results should contribute valuable L1 data to this expanding evidence base. ro-journal.biomedcentral.com/articles/10....
Research trends of selective internal radiation therapy for liver cancer: a bibliometric analysis - Radiation Oncology
Background Liver cancer is a major contributor to cancer-related mortality. Selective internal radiation therapy (SIRT) for liver cancer has garnered increasing attention. This study aims to comprehen...
ro-journal.biomedcentral.com
September 18, 2025 at 4:01 PM
As published in a recent JVIR article, Y90 post-procedure PET/SPECT imaging is shown to inform better patient follow-up. Looking forward to seeing how Eye90 microspheres Precision Dosimetry® compares to Y90 PET/SPECT when ABK’s Route90 clinical trial reads out. www.jvir.org/article/S105...
Prediction of Recurrence of Hepatocellular Carcinoma Following Radiation Segmentectomy with Resin Microspheres Based on Underdosed Tumor Volume on Yttrium-90 Positron Emission Tomography/CT Dosimetry
To evaluate the use of immediate post–yttrium-90 (90Y)-radiation segmentectomy (RS) positron emission tomography (PET)/computed tomography (CT) and dosimetry software in predicting incomplete response...
www.jvir.org
September 8, 2025 at 3:09 AM
ABK Biomedical Concludes Patient Enrollment in Pivotal ROUTE90 Study for Liver Cancer Treatment#Canada#Halifax#ABK_Biomedical#Eye90_microspheres#ROUTE90
ABK Biomedical Concludes Patient Enrollment in Pivotal ROUTE90 Study for Liver Cancer Treatment
ABK Biomedical has finalized patient enrollment in the ROUTE90 study. This pivotal clinical trial evaluates the Eye90 microspheres, a potential breakthrough in liver cancer treatment.
third-news.com
February 24, 2026 at 4:02 PM